Cephalosporin

Global Sepsis Therapeutics Strategic Research Report 2023-2024 and 2030: New Nanoparticles - A Revolution in the Development of Clinical Sepsis Therapy - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 24, 2024
Pharmaceutical, Health, Other Health, FDA, Common, Cephalosporin, Antimicrobial spectrum, Sepsis, Growth, Research, Therapy

The "Sepsis Therapeutics - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Sepsis Therapeutics - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
  • Common treatments for sepsis include antibiotics and vasopressors, with cephalosporins holding a significant share of the treatment market.
  • Despite the global economic update, the competitive landscape of the sepsis therapeutics market remains strong, with players worldwide categorized by their market presence.
  • The current standard of care involves antibiotics and vasopressors, with GIAPREZA being the only FDA-approved branded drug for sepsis treatment.

Antibiotic Drugs Market Analysis Report 2024: Surging Demand, Trends, and Forecasts 2019-2029 - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 29, 2024
Health, Pharmaceutical, Pfizer, Urinary tract infection, Merck, USD, GSK, Strategic planning, Cephalosporin, Pneumonia, Prevalence, Merck & Co., Meningitis, Infection, Pharmaceutical industry

The "Global Antibiotic Drugs Market (2024 Edition): Analysis By Drug Class (Cephalosporin, Penicillin, Macrolides, Fluoroquinolone, Others), Spectrum (Broad, Narrow), By Indication, By Region, By Country: Market Insights and Forecast (2019-2029)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Antibiotic Drugs Market (2024 Edition): Analysis By Drug Class (Cephalosporin, Penicillin, Macrolides, Fluoroquinolone, Others), Spectrum (Broad, Narrow), By Indication, By Region, By Country: Market Insights and Forecast (2019-2029)" report has been added to ResearchAndMarkets.com's offering.
  • The report meticulously evaluates the antibiotic drugs industry's landscape, emphasizing the key drug classes such as Cephalosporins, Penicillins, Macrolides, and Fluoroquinolones.
  • This investigation aligns with an increased emphasis on antibiotic stewardship and the urgent need for combating antibiotic resistance globally.
  • The Antibiotic Drugs Market report not only underscores the significant trends and growth drivers but also furnishes a detailed forecast, setting the stage for informed decision-making and strategic planning within the pharmaceutical sector.

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation of NRX-101 in Complicated Urinary Tract Infection and Pyelonephritis

Retrieved on: 
Tuesday, January 16, 2024
Intellectual property, Death, Clostridioides difficile infection, Patient, Research, DSM-IV codes, Hospital, Health, Urine, Dark Enlightenment, Colitis, Tuberculosis, UTI, Clostridioides difficile, DCS, Tetracycline, QIDP, Risk, Infection, Cephalosporin, Pulmonary fibrosis, Sepsis, FDA, Priority review, Penicillin, New Drug Application, Pyelonephritis, Urinary tract infection, Literature, Contra, NMDA, CNS, Pharmaceutical industry

Receipt of QIDP designation confers Priority Review, and critically, five additional years of data-exclusivity to NRX-101's already strong Intellectual Property position.

Key Points: 
  • Receipt of QIDP designation confers Priority Review, and critically, five additional years of data-exclusivity to NRX-101's already strong Intellectual Property position.
  • The FDA also granted NRX-101 Fast Track designation for cUTI, which additionally allows for rolling submission of the Company's New Drug Application.
  • On the basis of this advance, NRx is seeking partners with active involvement in urology, infectious disease and/or women's health for commercialization of NRX-101.
  • NRx thanks the US FDA for its rapid award of QIDP designation for cUTI and pyelonephritis.

Critical agreement paves way for new model to accelerate access to important antibiotics for serious bacterial infections

Retrieved on: 
Tuesday, September 12, 2023
Oncology, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, CHAI, US Foods, Gram, Infection, European Medicines Agency, National Rural Development Partnership, Pharmaceutics, AMR, PQ, Cephalosporin, Patient, Tuberculosis, Diagnosis, WHO, Death, Food, World Health Organization, Essential medicines, Pharmaceutical industry, Shionogi, Orchid

Launched in June 2022, the project represents a new model for bridging global gaps in equitable access to important antibiotics.

Key Points: 
  • Launched in June 2022, the project represents a new model for bridging global gaps in equitable access to important antibiotics.
  • Even though populations in low- and middle-income countries face a high burden of death from drug-resistant bacterial infections, their access to antibiotics with activity against resistant bacteria is usually delayed by more than a decade .
  • That situation may worsen given that the number of serious, potentially life-threatening, infections due to carbapenem-resistant bacteria has been growing across multiple regions , including South Asia and Latin America.
  • By addressing barriers that have historically limited the availability of important antibiotics in low- and middle-income countries, this innovative project aims to accelerate appropriate access for an affordable, quality-assured antibiotic to treat drug-resistant Gram-negative infections.

Results from Pivotal Phase 3 ATTACK Trial of Investigational Sulbactam-Durlobactam for Treatment of Serious Infections Caused by Acinetobacter Published in The Lancet Infectious Diseases

Retrieved on: 
Thursday, May 11, 2023
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Infectious Diseases, Clinical Trials, Priority review, Nephrotoxicity, Safety, Infection, Antimicrobial spectrum, New Drug Application, NDA, World Health Organization, Colistin, Acinetobacter, Gram-negative bacteria, Centers for Disease Control and Prevention, CDC, Acinetobacter baumannii, The Lancet, Aminoglycoside, Incidence, Death, Rutgers University, Cephalosporin, Robert Wood Johnson Medical School, Patient, Chronic kidney disease, Penicillin, Division, Carbapenem, Disease, PDUFA, Mortality, Nursing care plan, WHO, FDA, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Gene, MPH, Food, Pharmaceutical industry, Vaccine, MD

The study – Efficacy and Safety of Sulbactam-Durlobactam vs. Colistin for the Treatment of Patients with Serious Infections due to Acinetobacter Baumannii-Calcoaceticus Complex: a multicentre, randomised, active-controlled, Phase 3, non-inferiority clinical trial (ATTACK) – was first published online on May 11.

Key Points: 
  • The study – Efficacy and Safety of Sulbactam-Durlobactam vs. Colistin for the Treatment of Patients with Serious Infections due to Acinetobacter Baumannii-Calcoaceticus Complex: a multicentre, randomised, active-controlled, Phase 3, non-inferiority clinical trial (ATTACK) – was first published online on May 11.
  • The Phase 3 trial evaluated the safety and efficacy of sulbactam-durlobactam versus colistin in patients with infections caused by Acinetobacter.
  • In the trial, sulbactam-durlobactam demonstrated statistical non-inferiority versus colistin for the primary endpoint of 28-day all-cause mortality in patients with carbapenem-resistant Acinetobacter infections and a significant difference in clinical cure rates.
  • The sulbactam-durlobactam NDA has a Prescription Drug User Fee Act (PDUFA) target action date of May 29, 2023.

Sulbactam-Durlobactam Unanimously Recommended for Approval by FDA Advisory Committee

Retrieved on: 
Monday, April 17, 2023
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, Priority review, Nephrotoxicity, Infection, Antimicrobial spectrum, New Drug Application, NDA, Colistin, Acinetobacter, Gram-negative bacteria, Centers for Disease Control and Prevention, Committee, CDC, Acinetobacter baumannii, Aminoglycoside, Incidence, Death, Cephalosporin, MD, Patient, Chronic kidney disease, Penicillin, Carbapenem, Disease, PDUFA, Mortality, WHO, Therapy, Gene, Food, Safety, Pharmaceutical industry, Vaccine

The FDA will take the Committee’s recommendation into consideration when it makes a final determination.

Key Points: 
  • The FDA will take the Committee’s recommendation into consideration when it makes a final determination.
  • Infections caused by drug-resistant Acinetobacter are serious and life-threatening conditions associated with high morbidity and mortality1 and long, expensive hospital stays.
  • Globally, Acinetobacter baumannii was among the top six leading pathogens for deaths associated with resistance in 20193.
  • Carbpenem-resistant Acinetobacter is considered a Priority 1 pathogen by the World Health Organization (WHO)4.

Saudi Arabia Antibiotics Markets, Competition, Forecast & Opportunities, 2027 - Cephalosporin, Penicillin, Amoxicillin, Azithromycin, Clindamycin, Tetracycline - ResearchAndMarkets.com

Retrieved on: 
Friday, January 27, 2023
Infectious Diseases, Pharmaceutical, Health, Capsule, Administration, Penicillin, Urinary tract infection, Infection, Government, Virus, Viral, Investment, Cephalosporin, COVID-19, Disorder, Saudi Food and Drug Authority, Drug development, Market, Route of administration, Certification, Research, Ministry, Death, SFDA, Antibody, Disease, Sanofi, Growth, Spectrum, Bacteria, Clindamycin, Tablet, Grindeks, Pharmaceutical industry, Vaccine, Arms industry, Azithromycin, Amoxicillin, Sepsis, Tetracycline

Saudi Arabia antibiotics market is anticipated to register growth with an impressive CAGR in the forecast period, 2023-2027, on the account of increasing instances of infectious diseases.

Key Points: 
  • Saudi Arabia antibiotics market is anticipated to register growth with an impressive CAGR in the forecast period, 2023-2027, on the account of increasing instances of infectious diseases.
  • Saudi Arabia pharmaceutical industry grossed USD8.35 billion in the year 2019 that further registered growth of USD10.19 billion in 2020.
  • promotes the requirement for the antibiotics and thus supports the growth of the Saudi Arabia antibiotics market in the next five years.
  • Company Profiles: Detailed analysis of the major companies present in Saudi Arabia antibiotics market.

Animal Antibiotics and Antimicrobials Global Market to Reach $5.26 Billion by 2026 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 14, 2022
Pharmaceutical, Agriculture, Health, Natural Resources, Mode, Milk, Human, Diet, Asia-Pacific, Poultry, Meat, Acquisition, Bayer, Growth, Partnership, Industry, Egg, Tetracycline antibiotics, Solution, ADM, Research, PETS, Animal, Livestock, Aquaculture, Animal husbandry, Sulfonamide, Cephalosporin, Aminoglycoside, Elanco, Lincosamides, Macrolide, Penicillin, Injection, Quinolone antibiotic

The "Animal Antibiotics and Antimicrobials Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Animal Antibiotics and Antimicrobials Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.
  • North America was the largest region in the animal antibiotics and antimicrobials market in 2021.
  • The regions covered in the animal antibiotics and antimicrobials market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
  • Rising demand for animal-derived food products is driving the growth of the animal antibiotics and antimicrobials market.

Bruker Launches Unique LiquidArray® Multiplex PCR Assays

Retrieved on: 
Friday, April 22, 2022
Technology, Biotechnology, Health, Other Health, Pharmaceutical, Other Science, Other Technology, Research, Medical Devices, Infectious Diseases, General Health, Hardware, Science, Data Management, MALDI, Laboratory, RUO, Neisseria gonorrhoeae, Division of Acquired Immunodeficiency Syndrome, Tuberculosis, Service, Bruker, Mycobacterium, Cell biology, Classification, STI, XT, Yeast, Fluorescence, Quality control, Life, Bacteria, Research, Consumer Product Safety Improvement Act, MD–PhD, PCR, Fungus, Microscopy, IVD, Chlamydia trachomatis, Food, Technology, Congress, Infection, Nasdaq, Mycobacterium tuberculosis, Solution, Gene, Cephalosporin, Multimedia, Proteomics, MBT, TTR, Pharmaceutical industry, Vaccine, Fine chemical, Chlamydia, European, Microbiology, Neisseria

At the 32nd European Congress of Clinical Microbiology & Infectious Diseases ( www.eccmid.org ), Bruker Corporation (Nasdaq: BRKR) announces further advances in its market-leading MALDI Biotyper (MBT) platform, and launches new multiplex PCR infectious disease assays that are based on its proprietary LiquidArray technology.

Key Points: 
  • At the 32nd European Congress of Clinical Microbiology & Infectious Diseases ( www.eccmid.org ), Bruker Corporation (Nasdaq: BRKR) announces further advances in its market-leading MALDI Biotyper (MBT) platform, and launches new multiplex PCR infectious disease assays that are based on its proprietary LiquidArray technology.
  • Bruker also leverages its LiquidArray technology for the FluoroType STI PCR assay, which detects 9 targets from 7 sexually transmitted pathogens from clinical samples in a single test.
  • LiquidArray multiplex real-time PCR is a cost-effective, second-generation syndromic panel format for clinical laboratories.
  • In the unbound state, Lights-On probes cannot emit, and as fluorescence is either emitted or suppressed, specific fluorescence signatures are generated by the unique FluoroCycler XT thermocycler for the LiquidArray multiplex PCR technology.

Global Hospital Infection Therapeutics Market Report 2021: Market Reached a Value of Approx $11 Billion in 2020 - Trends, Share, Size, Growth, Opportunities and Forecast to 2026 - ResearchAndMarkets.com

Retrieved on: 
Monday, January 24, 2022
Hospitals, Pharmaceutical, Health, Research, Cell wall, Urinary tract infection, Tigecycline, Cephalosporin, Vaccine, Vancomycin, R, Nursing, Linezolid, COVID-19, Hospital-acquired pneumonia, Caspofungin, Industry, Infection, Hospital, Carbapenem, Subclinical infection, Therapy, Degenerative disease, Hospital-acquired infection, Bloodstream infections, Aminoglycoside, Antibiotics, Pharmaceutical industry, Fine chemical, Sex industry, Growth

The "Hospital Infection Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Hospital Infection Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.
  • The global hospital infection therapeutics market reached a value of around US$ 11 Billion in 2020.
  • How has the global hospital infection therapeutics market performed so far and how will it perform in the coming years?
  • What is the structure of the global hospital infection therapeutics market and who are the key players?